• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    AbbVie and SpinUp Foster Canadian Life Sciences Innovation with the Launch of the AbbVie Biotech Innovators Award

    9/26/24 8:00:00 AM ET
    $ABBV
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ABBV alert in real time by email
    • National competition, in collaboration with SpinUp, the University of Toronto's lab-based life sciences accelerator, demonstrates AbbVie's commitment to a thriving biotech ecosystem in Canada
    • One Canadian biotech will receive a year of laboratory space and equipment at no cost, as well as access to support and mentorship
    • Applications will be accepted until January 17, 2025

    TORONTO, Sept. 26, 2024 /CNW/ - AbbVie (NYSE:ABBV), jointly with the University of Toronto's SpinUp, today announced the launch of the AbbVie Biotech Innovators Award, a national prize to help foster innovation and support growth in Canada's life sciences sector.

    AbbVie Biotech Innovators Award (CNW Group/AbbVie Canada)

    AbbVie is pleased to collaborate with SpinUp, a purpose-built laboratory for chemistry and biological work—or wet lab—incubator at the University of Toronto, to support early-stage Canadian biotechnology startup companies with the potential to generate transformational therapies in areas that align with AbbVie's therapeutic areas of focus: immunology, oncology, neuroscience and eye care.

    The award, funded by AbbVie, will provide one early-stage biotech recipient with a year of laboratory space at no cost, in addition to access to SpinUp's core equipment, services, entrepreneurship programming and research talent community at the University of Toronto. The startup selected will also benefit from mentorship by AbbVie's scientific and business executives.

    "We are delighted to launch this exciting initiative, which demonstrates AbbVie's commitment to investing in Canada's world-class life sciences sector, growing our thriving biopharma ecosystem, and helping to accelerate the delivery of life-changing biopharmaceutical innovation to enhance the quality of life for patients in Canada and around the world," said Rami Fayed, Vice President and General Manager of AbbVie Canada. "Collaboration is a critical element needed to solve major health challenges, and we look forward to collaborating with SpinUp and the selected recipient to help advance meaningful health innovation."

    "The University of Toronto Mississauga is delighted to partner with AbbVie on the Biotech Innovators Award to accelerate a promising life science venture at SpinUp – our newest incubator," says Raquel De Souza, Director of Partnerships & Innovation at the University of Toronto Mississauga. "In response to the unique challenges faced by early-stage

    startups, we created SpinUp to provide subsidized access to a brand new, state-of-the-art research facility, robust entrepreneurship programming and world-leading research talent at the university. We hope Canadian innovators will be inspired to make their mark at U of T."  

    Applications are being accepted from today through January 17, 2025. For more information on the application requirements and judging criteria, or to submit an application, please visit: https://spinup.utm.utoronto.ca/biotech-innovators-award/.

    About AbbVie

    AbbVie's mission is to discover and deliver innovative medicines that solve serious health issues today and address the medical challenges of tomorrow. We strive to have a remarkable impact on people's lives across several key therapeutic areas – immunology, oncology, neuroscience, and vision care – and products and services in our Allergan Aesthetics portfolio. For more information about AbbVie, please visit us at www.abbvie.ca. Follow AbbVie Canada on Twitter, on Instagram, or find us on LinkedIn.

    About SpinUp

    SpinUp is the first wet lab startup incubator at the University of Toronto, Canada's leading centre for learning and discovery and one of the world's top-two universities for health science productivity. SpinUp is purpose built to drive life science innovation. It offers early-stage start-ups access to outstanding and highly subsidized wet lab space, equipment, entrepreneurship programming and expertise at a brand new, state-of-the-art research facility at U of T's Mississauga campus. Visit our website at spinup.utm.utoronto.ca and connect with us on X, Instagram, and LinkedIn.

    SpinUp is proudly part of U of T Entrepreneurship, a network of 12 accelerators across three campuses. Over the past ten years, this network has supported more than 650 capital-backed companies, which have created 10,000+ jobs and raised $2.5 billion in external investment.  U of T now launches more research-based start-ups than any university in North America outside of MIT. The AbbVie Biotech Innovators Award is part of U of T Mississauga's Blue Ticket program at SpinUp, which provides a one-year membership.

    SOURCE AbbVie Canada

    Cision View original content to download multimedia: http://www.newswire.ca/en/releases/archive/September2024/26/c8775.html

    Get the next $ABBV alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ABBV

    DatePrice TargetRatingAnalyst
    2/25/2026$260.00Outperform
    RBC Capital Mkts
    2/20/2026$275.00Overweight
    Barclays
    1/8/2026Outperform → Peer Perform
    Wolfe Research
    1/7/2026$240.00Neutral
    UBS
    12/10/2025$265.00Hold → Buy
    HSBC Securities
    11/13/2025$280.00Sector Outperform
    Scotiabank
    11/4/2025$237.00Buy → Hold
    DZ Bank
    10/14/2025Buy → Hold
    Erste Group
    More analyst ratings

    $ABBV
    SEC Filings

    View All

    AbbVie Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - AbbVie Inc. (0001551152) (Filer)

    4/3/26 4:05:55 PM ET
    $ABBV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by AbbVie Inc.

    SCHEDULE 13G/A - AbbVie Inc. (0001551152) (Subject)

    3/26/26 3:06:03 PM ET
    $ABBV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form DEFA14A filed by AbbVie Inc.

    DEFA14A - AbbVie Inc. (0001551152) (Filer)

    3/23/26 5:01:40 PM ET
    $ABBV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ABBV
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    RBC Capital Mkts initiated coverage on AbbVie with a new price target

    RBC Capital Mkts initiated coverage of AbbVie with a rating of Outperform and set a new price target of $260.00

    2/25/26 7:48:26 AM ET
    $ABBV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Barclays initiated coverage on AbbVie with a new price target

    Barclays initiated coverage of AbbVie with a rating of Overweight and set a new price target of $275.00

    2/20/26 8:23:14 AM ET
    $ABBV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    AbbVie downgraded by Wolfe Research

    Wolfe Research downgraded AbbVie from Outperform to Peer Perform

    1/8/26 8:35:39 AM ET
    $ABBV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ABBV
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Rapp Edward J

    4 - AbbVie Inc. (0001551152) (Issuer)

    4/2/26 5:00:14 PM ET
    $ABBV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Alpern Robert J

    4 - AbbVie Inc. (0001551152) (Issuer)

    4/2/26 5:00:11 PM ET
    $ABBV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Quaggin Susan E

    4 - AbbVie Inc. (0001551152) (Issuer)

    4/2/26 5:00:15 PM ET
    $ABBV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ABBV
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Erin Lichy Gets Real About Her Natrelle® Breast Augmentation

    The entrepreneur and mother of four shares her breast augmentation journey, from consultation to post-op, with Natrelle® breast implants. As a champion of authenticity, Lichy hopes her transparency will help normalize the conversation around breast surgery.IRVINE, Calif., April 14, 2026 /PRNewswire/ -- Allergan Aesthetics, an AbbVie company (NYSE:ABBV) has teamed up with New York-based entrepreneur and television personality, Erin Lichy. Lichy is opening up about her recent breast augmentation with market-leading Natrelle® breast implants in an effort to promote transparency and normalize conversations around aesthetic procedures. As a mom of four, and after years of breastfeeding, Lichy's d

    4/14/26 8:50:00 AM ET
    $ABBV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Haisco Enters into Exclusive License Agreement with AbbVie to Develop Novel Medicines for Pain

    BEIJING, April 13, 2026 /PRNewswire/ -- On April 10, 2026, Haisco Pharmaceutical Group Co., Ltd. (Ticker Code: 002653) announced that it has entered into an exclusive licensing agreement with AbbVie (NYSE:ABBV), a global biopharmaceutical company. Under the agreement, Haisco grants AbbVie the exclusive rights to develop, manufacture, and commercialize novel medicines for the treatment of pain globally, excluding mainland China, Hong Kong, and Macau. The program includes multiple compounds designed to address pain-related indications. These compounds are currently at various development stages in China, ranging from preclinical to Phase 1 clinical development."This collaboration is highly ali

    4/13/26 2:24:00 AM ET
    $ABBV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    AbbVie Showcases Late‑Breaking Phase 2 Data for Mirvetuximab Soravtansine-gynx (ELAHERE®) in Platinum‑Sensitive Ovarian Cancer (PSOC) at SGO 2026

    Results from the Phase 2 IMGN853-0420 trial show an objective response rate of 62.7% and consistent safety findings with mirvetuximab soravtansine-gynx (ELAHERE®) plus carboplatin followed by a continuation of mirvetuximab soravtansine monotherapy in patients with ≥50 % folate receptor alpha (FRα)-expressing, platinum-sensitive ovarian cancer (PSOC).Findings highlight mirvetuximab soravtansine's potential across the ovarian cancer treatment continuum. Data is being presented in a late-breaking oral presentation at the Society of Gynecologic Oncology (SGO) Annual Meeting. NORTH CHICAGO, Ill., April 12, 2026 /PRNewswire/ -- AbbVie (NYSE:ABBV) today announced that late-breaking results from the

    4/12/26 7:15:00 AM ET
    $ABBV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ABBV
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    FDA Approval for VYALEV issued to ABBVIE INC

    Submission status for ABBVIE INC's drug VYALEV (ORIG-1) with active ingredient FOSCARBIDOPA AND FOSLEVODOPA has changed to 'Approval' on 10/16/2024. Application Category: NDA, Application Number: 216962, Application Classification: Type 3 - New Dosage Form and Type 4 - New Combination

    10/18/24 4:38:13 AM ET
    $ABBV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    FDA Approval for VYALEV issued to ABBVIE INC

    Submission status for ABBVIE INC's drug VYALEV (ORIG-1) with active ingredient FOSCARBIDOPA AND FOSLEVODOPA has changed to 'Approval' on 10/16/2024. Application Category: NDA, Application Number: 216962, Application Classification: Type 3 - New Dosage Form

    10/17/24 1:29:31 PM ET
    $ABBV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    FDA Approval for SKYRIZI issued to ABBVIE INC

    Submission status for ABBVIE INC's drug SKYRIZI (SUPPL-7) with active ingredient RISANKIZUMAB-RZAA has changed to 'Approval' on 06/18/2024. Application Category: BLA, Application Number: 761262, Application Classification:

    6/21/24 4:38:17 AM ET
    $ABBV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ABBV
    Leadership Updates

    Live Leadership Updates

    View All

    AbbVie Appoints CEO Robert A. Michael as Chairman of the Board of Directors

    Richard A. Gonzalez to retire from the board of directors effective July 1, 2025NORTH CHICAGO, Ill., Feb. 14, 2025 /PRNewswire/ -- AbbVie (NYSE:ABBV) today announced that its board of directors has unanimously elected chief executive officer (CEO) Robert A. Michael to assume the additional position of chairman, effective July 1, 2025. He will succeed Richard A. Gonzalez, who formerly served as AbbVie's CEO and has been chairman since the Company's formation in 2013. "I want to extend my heartfelt gratitude to Rick for his remarkable leadership and dedicated service," said Roxanne S. Austin, lead independent director. "The board and I have complete confidence in Rob, and we are fortunate to

    2/14/25 7:40:00 AM ET
    $ABBV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    PureTech Founded Entity Seaport Therapeutics Names Lauren White as Chief Financial Officer

    Former ImmunoGen CFO will join Seaport to steer capital financing strategy, accounting, FP&A and investor relations PureTech Health plc (NASDAQ:PRTC, LSE: PRTC)) ("PureTech" or the "Company"), a clinical-stage biotherapeutics company, noted that its Founded Entity, Seaport Therapeutics, ("Seaport") a biopharmaceutical company that is advancing novel neuropsychiatric medicines with a proven strategy and team, today announced the appointment of Lauren White as Chief Financial Officer. An accomplished biotech financial executive, Ms. White most recently served as the Chief Financial Officer at ImmunoGen (NASDAQ:IMGN) prior to its acquisition by AbbVie (NYSE:ABBV) for $10.1 billion in 2024. T

    11/5/24 7:05:00 AM ET
    $ABBV
    $CCCC
    $IMGN
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)

    Seaport Therapeutics Names Lauren White as Chief Financial Officer

    Former ImmunoGen CFO will join Seaport to steer capital financing strategy, accounting, FP&A and investor relations Seaport Therapeutics ("Seaport or the "Company"), a clinical-stage biopharmaceutical company that is advancing novel neuropsychiatric medicines with a proven strategy and team, today announced the appointment of Lauren White as Chief Financial Officer. An accomplished biotech financial executive, Ms. White most recently served as the Chief Financial Officer at ImmunoGen (NASDAQ:IMGN) prior to its acquisition by AbbVie (NYSE:ABBV) for $10.1 billion in 2024. "I am so pleased to welcome Lauren as our CFO as we progress our clinical-stage pipeline of therapeutics for the treatme

    11/5/24 7:00:00 AM ET
    $ABBV
    $CCCC
    $IMGN
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)

    $ABBV
    Financials

    Live finance-specific insights

    View All

    AbbVie to Host First-Quarter 2026 Earnings Conference Call

    NORTH CHICAGO, Ill., March 31, 2026 /PRNewswire/ -- AbbVie (NYSE:ABBV) will announce its first-quarter 2026 financial results on Wednesday, April 29, 2026, before the market opens. AbbVie will host a live webcast of the earnings conference call at 8 a.m. Central time. It will be accessible through AbbVie's Investor Relations website at investors.abbvie.com. An archived edition of the session will be available later that day. About AbbVieAbbVie's mission is to discover and deliver innovative medicines and solutions that solve serious health issues today and address the medical challenges of tomorrow. We strive to have a remarkable impact on people's lives across several key therapeutic areas

    3/31/26 8:00:00 AM ET
    $ABBV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    AbbVie Declares Quarterly Dividend

    NORTH CHICAGO, Ill., Feb. 19, 2026 /PRNewswire/ -- The board of directors of AbbVie Inc. (NYSE:ABBV) today declared a quarterly cash dividend of $1.73 per share.  The cash dividend is payable May 15, 2026, to stockholders of record at the close of business on April 15, 2026.Since the company's inception in 2013, AbbVie has increased its dividend by more than 330 percent. AbbVie is a member of the S&P Dividend Aristocrats Index, which tracks companies that have annually increased their dividend for at least 25 consecutive years.About AbbVieAbbVie's mission is to discover and deliver innovative medicines and solutions that solve serious health issues today and address the medical challenges of

    2/19/26 9:37:00 AM ET
    $ABBV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    AbbVie Reports Full-Year and Fourth-Quarter 2025 Financial Results

    Reports Full-Year Diluted EPS of $2.36 on a GAAP Basis, a Decrease of 1.3 Percent; Adjusted Diluted EPS of $10.00, a Decrease of 1.2 Percent; These Results Include an Unfavorable Impact of $2.76 Per Share Related to 2025 Acquired IPR&D and Milestones Expense  Delivers Full-Year Net Revenues of $61.160 Billion, an Increase of 8.6 Percent on a Reported Basis and 8.5 Percent on an Operational Basis  Full-Year Global Net Revenues from the Immunology Portfolio Were $30.406 Billion, an Increase of 14.0 Percent on a Reported Basis, or 13.9 Percent on an Operational Basis; Global Skyrizi Net Revenues Were $17.562 Billion; Global Rinvoq Net Revenues Were $8.304 Billion; Global Humira Net Revenues Wer

    2/4/26 7:48:00 AM ET
    $ABBV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ABBV
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by AbbVie Inc. (Amendment)

    SC 13G/A - AbbVie Inc. (0001551152) (Subject)

    2/13/24 4:55:55 PM ET
    $ABBV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by AbbVie Inc. (Amendment)

    SC 13G/A - AbbVie Inc. (0001551152) (Subject)

    1/25/24 4:59:27 PM ET
    $ABBV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by AbbVie Inc. (Amendment)

    SC 13G/A - AbbVie Inc. (0001551152) (Subject)

    2/9/23 10:54:46 AM ET
    $ABBV
    Biotechnology: Pharmaceutical Preparations
    Health Care